An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users

• Published in: Contraception (Stoneham) 2024-01, Vol.129, p.110298-110298, Article 110298
• Main Authors: Diamond, Breea, Sheeder, Jeanelle, Lazorwitz, Aaron
• Format: Article
• Language: English
• Subjects: Contraceptive Agents, Female - adverse effects; contraceptive implant; Desogestrel - adverse effects; Drug Implants; etonogestrel; Female; Humans; mood changes; Patient Health Questionnaire-9 (PHQ-9); pharmacokinetics; Retrospective Studies; side effects
• ISSN: 0010-7824; 1879-0518
• DOI: 10.1016/j.contraception.2023.110298

To evaluate if inter-individual variability in serum etonogestrel (ENG) concentrations accounts for variability in mood-related side effects among ENG implant users. Participants underwent a single-time blood draw for measurement of serum ENG concentrations using a liquid-chromatography mass-spectrometry assay, and completed a questionnaire at enrollment that retrospectively assessed mood-related side effects during the period of implant use. For a subset of participants, PHQ-9 scores, obtained for other clinical purposes, were also compared. We used independent medians tests and linear regression to evaluate associations between mood symptoms and serum ENG concentrations as our primary outcome. Among 900 enrolled participants, 34% (306/900) reported mood changes on the baseline questionnaire. Of these, 31 (3.4%) participants also had documented PHQ-9 scores. Serum ENG concentrations (median 126.9pg/mL [range 39.4-695.1]) were not associated with reported mood changes on the questionnaire (p=0.19) or on the PHQ-9 (β= 0.00, 95% CI -0.03, 0.03). Pharmacokinetic variability does not explain the inter-individual variability in mood-related side effects among ENG implant users. Mood-related side effects and altered mental health metrics are commonly reported by etonogestrel contraceptive implant users but demonstrate wide inter-individual variability. Individual differences in serum drug levels do not appear to account for this variability in mood-related side effects, and so future research should focus on novel personal factors.